Nexalin taps Alumni Capital for $750K, opens door to $15M more
What's the deal? Nexalin TechnologyDealroom has a profile for this one. Try Dealroom → (NASDAQ: NXL) has raised $750,000 through a registered direct offering, selling 2,419,355 shares at $0.31 each to a single institutional investor, Alumni Capital LPDealroom has a profile for this one. Try Dealroom →. The agreement was signed on August 19, 2026, and expected to close the following day.
The fine print: Nexalin will also issue warrants to buy up to 1,209,677 shares at $0.50 each, exercisable immediately and expiring in one year. If exercised in full for cash, they would add $604,839 in gross proceeds. Maxim GroupDealroom has a profile for this one. Try Dealroom → acted as non-exclusive financial advisor for a $100,000 cash fee.
The bigger line: In a concurrent deal with Alumni Capital, Nexalin secured an "any market purchase agreement" letting it sell up to $15 million in shares over time. The facility runs until December 31, 2027, with each purchase capped at $1 million — or $5 million by mutual agreement.
Why now? The structure gives Nexalin immediate cash plus a standing option to raise more without a fresh offering each time. Shares under the facility would be priced at a discount: either 92% of the lowest three-day volume-weighted average price, or 97% of the prior day's lowest traded price.
What could go wrong? The equity line is a potential source of significant dilution, especially at discounted pricing. Nexalin must file a resale registration statement within 20 business days, facing a $175,000 penalty if it misses the deadline or the filing is not declared effective within 60 days.
The signal: For a small-cap company, pairing a modest direct raise with a much larger equity line is a way to lock in near-term capital while keeping a flexible funding channel open — a trade-off that hands the company runway at the cost of future dilution risk.
Read more: MiniChart
Image credit: Versal
